Comorbidities, bone-sparing agent prescription history and their determinants among postmenopausal women in UK primary care settings: a retrospective database study

Archives of Osteoporosis

Volumn 10, Issue 1, 2015, Pages 1-11

  Feudjo Tepie, M ^a   Ferguson, S ^a   Roddam, A ^b   Taylor, A ^a   Bayly, J ^c   Critchlow, C ^d  

^a AMGEN LTD   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF DERBY   (United Kingdom)

^d AMGEN INC   (United States)

Author keywords

Bone sparing agents; Clinical Practice Research Datalink; Comorbidities; Discontinuation; Postmenopausal osteoporosis; Switching

Indexed keywords

ALENDRONIC ACID; ALENDRONIC ACID PLUS COLECALCIFEROL; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ETIDRONIC ACID; GLUCOCORTICOID; IBANDRONIC ACID; IMMUNOSUPPRESSIVE AGENT; PARATHYROID HORMONE[1-34]; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CHRONIC LIVER DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; DIABETES MELLITUS; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; HEART DISEASE; HIP FRACTURE; HUMAN; HYPERTHYROIDISM; IRRITABLE COLON; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; OBSERVATIONAL STUDY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIMARY OSTEOPOROSIS; PRIORITY JOURNAL; REFERENCE DATABASE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SECONDARY OSTEOPOROSIS; SPINE FRACTURE; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED KINGDOM; VERY ELDERLY; GASTROINTESTINAL DISEASES; GREAT BRITAIN; HEART DISEASES; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PRIMARY HEALTH CARE; RENAL INSUFFICIENCY;

AGED; ANTICONVULSANTS; BONE DENSITY CONSERVATION AGENTS; COMORBIDITY; DIPHOSPHONATES; FEMALE; GASTROINTESTINAL DISEASES; GREAT BRITAIN; HEART DISEASES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; PRIMARY HEALTH CARE; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES;

EID: 84947802379     PISSN: 18623522     EISSN: 18623514     Source Type: Journal    
DOI: 10.1007/s11657-015-0233-4     Document Type: Article

References (48)

1. Bouillon R, Burkhardt P, Christiansen C, Fleisch HA, Fujita T, Gennari C, Martin TJ, Mazzuoli G, Melton LJ, Ringe JD (1991) Consensus development conference: prophylaxis and treatment of osteoporosis. Osteoporos Int 1:114–117
2. Scottish Intercollegiate Guidelines Network (2003) National Clinical Guideline 71: Management of osteoporosis. Available at: http://www.sign.ac.uk/pdf/sign71.pdf. Accessed July 2014
3. American Association of Clinical Endocrinologists Osteoporosis Task Force (2001) American Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract 7:293–312
4. International Osteoporosis Foundation (2012) Europe guidelines. Available at: http://www.iofbonehealth.org/europe-guidelines. Accessed 30 April 2014
5. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R, European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428
6. Cramer A, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023–1031
7. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541
8. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687–694
9. Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344–1352
10. Reginster JY, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R, Vertebral Efficacy with Risedronate Therapy (VERT) Study Group (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83–91
11. Hooper MJ, Ebeling PR, Roberts AP (2005) Risedronate prevents bone loss in early postmenopausal women: a prospective, randomized controlled trial. Climacteric 8:251–262
12. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata Y, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468
13. Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453–1460
14. McCombs JS, Thibaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287
15. Netelenbos JC, Geusens PP, Ypma G, Buijs SJ (2011) Adherence and profile of non-persistence in patients treated for osteoporosis—a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int 22:1537–1546
16. Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T (2012) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 23:223–231
17. Martin KE, Yu J, Campbell HE, Abarca J, White TJ (2011) Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost. J Manag Care Pharm 17:596–609
18. Hoffmann F, Jung TI, Felsenberg D, Glaeske G (2008) Pattern of intravenous bisphosphonate use in outpatient care in Germany. Pharmacoepidemiol Drug Saf 17:896–903
19. Foster SA, Foley KA, Meadows ES, Johnston JA, Wang S, Pohl GM, Long SR (2007) Characteristics of patients initiating teriparatide for the treatment of osteoporosis. Osteoporos Int 19:373–377
20. Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA (2010) Adoption of once-monthly oral bisphosphonates and the impact on adherence. Am J Med 123:275–280
21. Abelson A, Ringe JD, Gold DT, Lange JL, Thomas T (2010) Longitudinal change in clinical fracture incidence after initiation of bisphosphonates. Osteoporos Int 21:1021–1029
22. Middleton ET, Steel SA, Doherty SM (2007) The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice. Calcif Tissue Int 81:335–340
23. Lawson DH, Sherman V, Hollowell J (1998) The general practice research database for the scientific and ethical advisory group. Q J Med 91:445–452
24. Garcia Rodriguez LA, Perez Gutthann S (1998) Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol 45:419–425
25. Gallagher A, Rietbrock S, Olson M, van Staa TP (2008) Fracture outcomes related persistence and compliance with oral bisphosphonate. J Bone Miner Res 23:1569–1575
26. Rietbrock S, Olson M, van Staa TP (2009) The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. Q J Med 102:35–42
27. Jick H, Terris BZ, Derby LE, Jick SS (1992) Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1:347–349
28. Walley T, Mantgani A (1997) The UK general practice research database. Lancet 350:1097–1099
29. Agresti A, Booth J, Hobert JP, Caffo B (2008) Random-effects modeling of categorical response data. Sociol Methodol 30:27–80
30. Penning-van Beest FJ, Goettsh WG, Erkens JA, Herings RM (2006) Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 28:236–242
31. National Institute for Health and Care Excellence (2011) TA160 Osteoporosis – primary prevention. Available at: http://guidance.nice.org.uk/TA160. Accessed 30 April 2014
32. National Institute for Health and Care Excellence (2011) TA161 Osteoporosis – secondary prevention. Available at: http://www.nice.org.uk/guidance/ta161/resources/ta161-osteoporosis-secondary-prevention-including-strontium-ranelate-understanding-nice-guidance2. Accessed 30 April 2014
33. Watts NB, Worley K, Solis A, Doyle J, Sheer R (2004) Comparison of risedronate to alendonate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm 10:142–152
34. National Institute for Health and Care Excellence (2014) Osteoporosis overview. Available at: http://pathways.nice.org.uk/pathways/osteoporosis#content=view-node%3Anodes-secondary-prevention-of-osteoporotic-fragility-fractures-in-postmenopausal-women. Accessed 20 July 2015.
35. Biskobing DM (2002) COPD and osteoporosis. Chest 121:609–620
36. Royal College of Physicians (2011) Falling standards, broken promises: report of the national audit of falls and bone health in older people 2010. Available at: https://www.rcplondon.ac.uk/sites/default/files/national_report.pdf. Accessed 20 July 2015
37. Balasubramanian A, Brookhart MA, Goli V, Critchlow CW (2013) Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women. Int J Gen Med 6:839–848
38. Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S, Treatment of Osteoporosis in clinical Practice (TOP) Study Group (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 914
39. Blouin J, Dragomir A, Ste-Marie L, Fernandes JC, Perreault S (2007) Discontinuation of antiresorptive therapies: a comparison between 1998–2001 and 2002–2004 among osteoporotic women. J Clin Endocrinol Metab 92:887–894
40. Lo JC, Pressman AR, Omar MA, Ettinger B (2006) Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 17:922–928
41. Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Brookhart MA (2005) Compliance with osteoporosis medications. Arch Intern Med 165:2414–2419
42. Dennison EM, Compston JE, Flahive J et al (2013) Effect of comorbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 50:1288–1293
43. Ensrud KE (2013) Fracture risk in CKD. Clin J Am Soc Nephrol 8:1282–1283
44. Nazareth I, King M, Haines A, Rangel L, Myers S (1993) Accuracy of diagnosis on general practice computer system. BMJ 307:32–34
45. Hippisley-Cox J, Bayly J, Potter J, Fenty J, Parker C. Evaluation of standards of care for osteoporosis and falls in primary care. 2007. Available at: http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/general-practice/evaluation-of-standards-of-care-for-osteoporosis-and-falls-in-primary-care. Accessed 30 April 2015
46. Boonen S, Kay R, Cooper C, Haentjens P, Vanderschueren D, Callewaert F, Milisen K (2009) Osteoporosis management: a perspective based on bisphosphonate data from randomised clinical trials and observational databases. Int J Clin Pract 63:1792–1804
47. Soriano JB, Maier WC, Visick G, Pride NB (2001) Validation of general practitioner-diagnosed COPD in the UK general practice research database. Eur J Epidemiol 17:1075–1080
48. Li L, Roddam A, Ferguson S, Feudjo-Tepie M, Taylor A, Jick S (2014) Switch patterns of osteoporosis medication and its impact on persistence among postmenopausal women in the U.K. General Practice Research Database. Menopause 21:1106–1113